• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢囊腺癌细胞核DNA含量及形态学参数的定量研究

[A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma].

作者信息

Liu C, Zhao Y, Sun X

机构信息

Affiliate Hospital of Qingdao Medical College.

出版信息

Zhonghua Fu Chan Ke Za Zhi. 1995 Dec;30(12):738-40.

PMID:8728920
Abstract

OBJECTIVE

To study nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma.

METHODS

Nuclear DNA content and morphological parameters were quantitatively determined by image analysis technology in 56 cases of ovarian cystadenocarcinoma, 12 benign ovarian cystadenoma and 10 normal ovarian epithelial tissue.

RESULTS

DNA content of ovarian cystadenocarcinoma was the highest among the three groups; and there were significant differences between the groups (P < 0.01). In the aspect of morphometry, nuclear circle was greatly different among the three groups (P < 0.01). There was no significant variances in nuclear parameter and area (P > 0.05). Nuclear DNA content of ovarian cystadenocarcinoma was related to its histopathological classification, histological grade and clinical stages (P < 0.01, P < 0.05). There was a reverse relationship between the DNA ploidy level and clinical prognosis. The 2-year survival rate of ovarian cystadenocarcinoma with diploidy/near diploidy pattern was higher than that with aneuploid pattern (P < 0.01).

CONCLUSIONS

Nuclear DNA content of ovarian cystadenocarcinoma is a useful marker in reflecting the biological behavior and is of practical value in diagnosis, the choice of treatment methods and in the evaluation of results and prognosis.

摘要

目的

研究卵巢囊腺癌的核DNA含量及形态学参数。

方法

采用图像分析技术对56例卵巢囊腺癌、12例良性卵巢囊腺瘤及10例正常卵巢上皮组织进行核DNA含量及形态学参数的定量测定。

结果

卵巢囊腺癌的DNA含量在三组中最高,组间差异有统计学意义(P < 0.01)。在形态测量方面,三组间核圆形度差异有统计学意义(P < 0.01),核参数及面积差异无统计学意义(P > 0.05)。卵巢囊腺癌的核DNA含量与其组织病理学分类、组织学分级及临床分期相关(P < 0.01,P < 0.05)。DNA倍体水平与临床预后呈负相关。二倍体/近二倍体模式的卵巢囊腺癌2年生存率高于非整倍体模式(P < 0.01)。

结论

卵巢囊腺癌的核DNA含量是反映生物学行为的有用标志物,对诊断、治疗方法的选择及结果和预后评估具有实际价值。

相似文献

1
[A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma].卵巢囊腺癌细胞核DNA含量及形态学参数的定量研究
Zhonghua Fu Chan Ke Za Zhi. 1995 Dec;30(12):738-40.
2
[Prognostic significance of cellular DNA content and AgNOR count in ovarian cystadenoma].[卵巢囊腺瘤中细胞DNA含量及核仁组成区嗜银蛋白计数的预后意义]
Ai Zheng. 2003 Jan;22(1):62-5.
3
[Relation between DNA content in ovarian cystadenoma and its pathohistology].卵巢囊腺瘤DNA含量与其病理组织学的关系
Zhonghua Fu Chan Ke Za Zhi. 1993 Dec;28(12):731-3, 760-1.
4
Association of decreased mitochondrial DNA content with ovarian cancer progression.线粒体DNA含量降低与卵巢癌进展的关联。
Br J Cancer. 2006 Oct 23;95(8):1087-91. doi: 10.1038/sj.bjc.6603377. Epub 2006 Oct 3.
5
DNA content and morphological parameters in synovial sarcoma and synovioma.滑膜肉瘤和滑膜瘤中的DNA含量及形态学参数
Chin Med J (Engl). 1995 Oct;108(10):760-3.
6
[Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].卵巢交界性肿瘤和癌的临床病理分析及细胞周期蛋白D1和p53的表达
Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32.
7
[Clinical and pathological features of borderline ovarian tumors].[卵巢交界性肿瘤的临床及病理特征]
Zhonghua Fu Chan Ke Za Zhi. 2003 Feb;38(2):81-4.
8
[Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].[尿激酶型纤溶酶原激活剂和纤溶酶原激活剂抑制物-1在上皮性卵巢癌中的表达及临床意义]
Ai Zheng. 2007 Mar;26(3):312-7.
9
[Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].[具有二倍体DNA干细胞系的卵巢浆液性和黏液性交界性肿瘤的临床行为。保留器官和非保留器官治疗后的随访研究]
Zentralbl Gynakol. 2000;122(5):274-9.
10
Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors.
Obstet Gynecol. 1986 Apr;67(4):478-82.